179 related articles for article (PubMed ID: 23553326)
1. Accommodating missingness when assessing surrogacy via principal stratification.
Elliott MR; Li Y; Taylor JM
Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
[TBL] [Abstract][Full Text] [Related]
2. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
Conlon AS; Taylor JM; Elliott MR
Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
[TBL] [Abstract][Full Text] [Related]
3. Surrogacy marker paradox measures in meta-analytic settings.
Elliott MR; Conlon AS; Li Y; Kaciroti N; Taylor JM
Biostatistics; 2015 Apr; 16(2):400-12. PubMed ID: 25236906
[TBL] [Abstract][Full Text] [Related]
4. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
Taylor JM; Conlon AS; Elliott MR
Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
[TBL] [Abstract][Full Text] [Related]
5. A bayesian approach to surrogacy assessment using principal stratification in clinical trials.
Li Y; Taylor JM; Elliott MR
Biometrics; 2010 Jun; 66(2):523-31. PubMed ID: 19673864
[TBL] [Abstract][Full Text] [Related]
6. Solutions for surrogacy validation with longitudinal outcomes for a gene therapy.
Roberts EK; Elliott MR; Taylor JMG
Biometrics; 2023 Sep; 79(3):1840-1852. PubMed ID: 35833874
[TBL] [Abstract][Full Text] [Related]
7. Surrogacy assessment using principal stratification and a Gaussian copula model.
Conlon A; Taylor J; Elliott MR
Stat Methods Med Res; 2017 Feb; 26(1):88-107. PubMed ID: 24947559
[TBL] [Abstract][Full Text] [Related]
8. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
Li Y; Taylor JM; Elliott MR; Sargent DJ
Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
[TBL] [Abstract][Full Text] [Related]
9. Links between causal effects and causal association for surrogacy evaluation in a gaussian setting.
Conlon A; Taylor J; Li Y; Diaz-Ordaz K; Elliott M
Stat Med; 2017 Nov; 36(27):4243-4265. PubMed ID: 28786131
[TBL] [Abstract][Full Text] [Related]
10. Counterfactual links to the proportion of treatment effect explained by a surrogate marker.
Taylor JM; Wang Y; Thiébaut R
Biometrics; 2005 Dec; 61(4):1102-11. PubMed ID: 16401284
[TBL] [Abstract][Full Text] [Related]
11. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
Tanaka S; Matsuyama Y; Ohashi Y
Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
[TBL] [Abstract][Full Text] [Related]
12. Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints.
Wolfson J; Henn L
Emerg Themes Epidemiol; 2014; 11():14. PubMed ID: 25342953
[TBL] [Abstract][Full Text] [Related]
13. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
[TBL] [Abstract][Full Text] [Related]
14. Proportion of treatment effect mediated by surrogate endpoints.
Kuroki M; Shingaki R; Qu Y
Biom J; 2021 Jan; 63(1):105-121. PubMed ID: 33200481
[TBL] [Abstract][Full Text] [Related]
15. Principal stratification in causal inference.
Frangakis CE; Rubin DB
Biometrics; 2002 Mar; 58(1):21-9. PubMed ID: 11890317
[TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
17. Likelihood-based methods for evaluating principal surrogacy in augmented vaccine trials.
Liu W; Zhang B; Zhang H; Zhang Z
Stat Methods Med Res; 2017 Apr; 26(2):984-996. PubMed ID: 25549966
[TBL] [Abstract][Full Text] [Related]
18. Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data.
Chen H; Geng Z; Zhou XH
Biometrics; 2009 Sep; 65(3):675-82. PubMed ID: 18759847
[TBL] [Abstract][Full Text] [Related]
19. Evaluating candidate principal surrogate endpoints.
Gilbert PB; Hudgens MG
Biometrics; 2008 Dec; 64(4):1146-54. PubMed ID: 18363776
[TBL] [Abstract][Full Text] [Related]
20. A measure of the proportion of treatment effect explained by a surrogate marker.
Wang Y; Taylor JM
Biometrics; 2002 Dec; 58(4):803-12. PubMed ID: 12495134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
